Related Experiment Video
Updated: Jun 20, 2026
07:02
A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development
Published on: February 11, 2019
Cost-utility in CNS drug trials
Summary
Conducting cost-utility analyses in clinical trials presents significant theoretical and practical challenges. Researchers should prioritize cost-effectiveness, cost-benefit, and quality-of-life assessments over utility measurements.
Area of Science:
- Health Economics
- Clinical Trial Methodology
- Decision Science
Background:
- Cost-utility analysis (CUA) is increasingly used in healthcare decision-making.
- Integrating CUA into clinical trials requires measuring health state utilities.
- Existing utility measurement methods face theoretical and practical limitations.
Purpose of the Study:
- To critically evaluate the theoretical and practical challenges of conducting cost-utility analyses alongside clinical trials.
- To assess the validity and feasibility of different utility measurement instruments.
- To provide recommendations for economic evaluations in clinical settings.
Main Methods:
- Review of theoretical assumptions underlying utility measurement.
- Discussion of practical challenges in administering utility instruments within clinical trials.
- Comparative analysis of the standard gamble and other utility measurement techniques.
Main Results:
- Utility measurement in clinical trials relies on questionable theoretical assumptions and empirically invalid premises.
- The standard gamble, while the most validated method, is assumption-heavy, costly, and difficult to implement.
- Alternative utility instruments demonstrate lower validity compared to the standard gamble.
Conclusions:
- The theoretical and practical difficulties render utility measurement in clinical trials problematic.
- Investigators are advised against using utility assessments in CUA within clinical trials.
- Alternative economic endpoints such as cost-effectiveness, cost-benefit, and quality of life are recommended.
Related Concept Videos
01:29Drug Delivery: Parenteral Route
The parenteral route is a critical method of drug administration. It delivers compounds directly into the systemic circulation and bypasses the gastrointestinal tract. This approach is particularly advantageous for drugs that exhibit poor absorption or instability when administered orally.
There are three primary parenteral routes: intravenous (IV), intramuscular (IM), and subcutaneous (SC). The IV route introduces the drug directly into the bloodstream, ensuring immediate action. The IM route...
There are three primary parenteral routes: intravenous (IV), intramuscular (IM), and subcutaneous (SC). The IV route introduces the drug directly into the bloodstream, ensuring immediate action. The IM route...
01:11Clinical Trials: Overview
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).
01:09Bioequivalence of Drugs: Drugs with Multiple Indications
The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each indication due to...
01:22Dose-Response Relationship: Potency and Efficacy
The potency of a drug is the measure of its ability to produce a biological response and can be compared by looking at the half-maximum effective concentration or EC50 values of different drugs. A lower EC50 value indicates higher potency of the drug. In the dose–response curve of two antihypertensive drugs, candesartan and irbesartan, a significant difference is observed in their EC50 values. A lower EC50 value for candesartan indicates that it is more potent than irbesartan, as it produces...